INCY vs MRK
Incyte vs Merck & Co. — AI-powered side-by-side comparison
| Metric | INCY | MRK |
|---|
| AI Score |
72
|
70
|
| Price |
$121.08
|
$130.34
|
| P/E Ratio |
14.89×
|
103.53×
|
| ROE |
24.9%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
92.6%
|
75.4%
|
| Debt / Equity |
0.01×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
56.2
|
64.5
|
| Beta |
0.769
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for INCY versus MRK.
INCY leads by 2 points.
INCY scores 72/100 (Buy) versus MRK at 70/100 (Buy).
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical